Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte ™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval PRINCETON, N.J., Feb. 14, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials